KPC
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections (NCT04785924) | Wake Forest University Health Sciences | 2021-06-07 |
Track KPC automatically
Every clearance here is in the API, with alerts when new ones post.